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similarmedication adherence and total medical costs however; exenatide patients
had significantly lower total pharmacy costs.
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OBJECTIVES: To evaluate the cost-effectiveness of alternative renal screening
strategies and implications for blood pressure treatment in patients with type 1
diabetes. This required development of a discrete time simulationmodel for type 1
diabetes patients to estimate quality-adjusted life years (QALYs). METHODS: We
synthesized evidence on type 1 diabetes patients using several published sources.
The simulation model was based on eleven equations to estimate transitions be-
tween health states. Screening identified patients with impaired renal function
whom were then assigned angiotensin-converting enzyme inhibitors (ACE-I) to
lower blood pressure and improve renal function. Screening intervals were varied
from 1 year to 10 yearly intervals and compared to current UK guidelines of annual
screening. Outcomes were expressed in QALYs based on utilities of different dia-
betes complications obtained from a meta-analysis. Costs of the monitoring pro-
gram, treatment and hospitalisation from diabetes-related complications were in-
cluded. 1000 patients (mean age 15 years) were simulated for 85 years and cost-
effectiveness analyses performed. Costs and effects were discounted at standard
rates. Uncertainty surrounding these results was also calculated. RESULTS:When
comparing annual screening to biennial screening, the reduction in the number of
patients on ACE-I reduces both costs and QALYs, showing an incremental cost-
effectiveness (ICER) ratio of £9,718 per QALY. Increasing the screening interval to 5
years resulted in further reductions in both costs and QALYs, and an ICER well
within the National Institute of Health and Clinical Excellence’s (NICE) recom-
mended threshold. Sensitivity analyses showed universal treatment increased
survival rates when compared to annual screening and no treatment by an addi-
tional 4.4 and 5.5 years, respectively. CONCLUSIONS: Renal screening for people
with type 1 diabetes is cost-effective in the UK context compared to other funded
health interventions. Further research is required to determine whether universal
treatment is a policy that is worth pursuing in the long term.
PDB53
COST-EFFECTIVENESS OF SAXAGLIPTIN (ONGLYZA®) IN TYPE 2 DIABETES IN
SOUTH AFRICA
Juarez-Garcia A1, Casalvolone D2, Qatami L3, Bergenheim K4, Donato BMK5
1Bristol-Myers Squibb Company, Mexico, DF, Mexico, 2Bristol-Myers Squibb Company,
Bedforview, South Africa, 3Bristol-Myers Squibb Company, Dubai, United Arab Emirates,
4AstraZeneca, Mölndal, Sweden, 5Bristol-Myers Squibb Company, Wallingford, CT, USA
OBJECTIVES: It is currently estimated that 2 million South Africans suffer from
Type 2 Diabetes. Experts agree that the burden of diabetes is unacceptably high.
Thus access to appropriate treatment is a priority for the country. The objective of
this study was to investigate the cost effectiveness of saxagliptin (Onglyza®), a
DPP-4 inhibitor, plus metformin compared with a sulphonylurea (SU) plus met-
formin (MET) in South African patients not well controlled on metformin alone.
METHODS:Data from a 52 week clinical trial comparing saxagliptin and sulphony-
lurea in combination with metformin was used in a simulation model to estimate
long term complications in a cohort of type 2 diabetes patients. The model esti-
mates the incidence of microvascular andmacrovascular complications, diabetes-
specific mortality, all-cause mortality, and ultimately, costs and quality-adjusted
life years (QALYs) associated with the investigated treatment strategies. Costs and
QALYs were estimated for a lifetime time horizon and discounted at 5%. The per-
spective of private health care funders was used. RESULTS: Compared with SU
MET, the cost per QALY gainedwith saxagliptinMET is approximately ZAR 35,566.
Patients on saxagliptinMET gain 0.1 QALYs on average when compared to SU
MET, at an incremental cost of around ZAR 3775. The cost-effectiveness results
were robust to various sensitivity analyses. The improvement in quality of life was
associated mainly with lower incidence of hypoglycaemic events and modest re-
ductions in both macro and micro vascular complications in the cohort receiving
saxagliptin plus metformin compared with SUMET. CONCLUSIONS: This study
demonstrates that, over a patient’s lifetime, the addition of saxagliptin to met-
formin is associated with improvements in quality-adjusted life years compared
with SU in patients with type 2 diabetes. Saxagliptin treatment is a cost-effective
treatment alternative for type 2 diabetes in patients not well-controlled on met-
formin alone.
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OBJECTIVES: To evaluate the cost-effectiveness of saxagliptin plusmetformin ver-
sus sulfonylurea plus metformin in T2DM patients, who cannot achieve glycemic
goals with metformin monotherapy, in Colombia. METHODS: Cost effectiveness
analysis was performed using a discrete event simulation model with fixed time
steps (Cardiff Diabetes Model). The characteristics of the patients included in this
study and the efficacy profile for each treatment were obtained from the published
literature. The cost of medication was obtained from SISMED and Farmaprecios,
and the macro and microvascular events were based on POS tariffs, SOAT Manual
and consultationwith a local expert. The timehorizonwas 20 years and the applied
discount rate on costs and benefits was 3.5%. One-way and probabilistic sensitivity
analyses were performed for parameters and model assumptions. RESULTS: The
group treated with saxagliptin combination had fewer fatal and nonfatal events
and fewer episodes of hypoglycemia than the sulfonylurea combination popula-
tion. In both treatment groups the costs are driven by drug costs and treatment
costs associated with myocardial infarction. The incremental cost of saxagliptin
combination therapy over 20 years was US$555.552. Treatment with saxagliptin
plusmetformin resulted in a greater number of quality-adjusted life years (QALYs)
and life-years gained (LYG) than the sulfonylurea combination (9.758 vs. 9.504 and
11.786 vs. 11.758 respectively). The cost per QALY gained was US$2190. Cost-effec-
tiveness results were robust to sensitivity analysis. CONCLUSIONS: Considering
the GDP per capita in Colombia (US$6,348), our results suggest that the addition of
saxagliptin tometformin in patientswho do not achieve adequate glycemic control
withmetforminmonotherapy, is highly cost-effective compared with the addition
of sulfonylurea.
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OBJECTIVES:Analog insulin has become increasingly popular despite higher per
unit price compared to human insulin. This study evaluated the cost-effective-
ness of two premixed analog insulin preparations, compared with long-acting
analog insulin (LAAI) and pre-mixed human insulin (PHI) from the perspective
of a UK health care payer.METHODS: The CORE Diabetes Model (IMS Health) was
used to evaluate the cost-effectiveness of biphasic insulin [insulin lispro 75/25
(LM75/25) and 50/50 (LM50/50)] versus LAAI and PHI. Treatment effects were
taken directly from a recent Agency for Healthcare Research and Quality (AHRQ)
meta-analysis, while pharmacy, complication and patient management costs
were taken from published sources, expressed in 2008 pounds sterling. Future
costs and clinical benefits were discounted at 3.5% per annum. Sensitivity anal-
yses included: A1C effect, relative risk (RR) of hypoglycemia, time horizon, dis-
count rate, diabetes treatment and complication costs, and method of quality
adjusted life expectancy estimation. RESULTS: LM75/25 and LM50/50 increased
discounted quality-adjusted life expectancy (QALE) by 0.10 and 0.12 quality-
adjusted life years (QALYs), respectively, and reduced total lifetime direct med-
ical costs (LM75/25:£20,809 LAAI:£22,234; LM50/50:£20,680 LAAI:£21,292), domi-
nating LAAI. Compared to PHI, both LM75/25 and LM50/50 increased QALE (by
0.03 QALYs) and total lifetime direct medical costs (LM75/25/LM50/50:£18,499
PHI:£18,494), resulting in an incremental cost effectiveness ratio of £146/QALY
on a weighted mean A1C benefit of 0.06% in both cases. The only sensitivity
analyses in which LM75/25 and LM50/50 were not cost-effective compared to
LAAI or PHI were those in which the least favorable bound of the 95% confidence
intervals for RR of hypoglycemia or A1C difference were used. CONCLUSIONS:
Based on the findings of the AHRQ meta-analysis, and assuming a cost/QALY
threshold of £30,000/QALY, LM75/25 and LM50/50 would be considered cost-effec-
tive when compared with PHI and dominant when compared with LAAI from the
perspective of the UK health care payer.
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OBJECTIVES: Effective glycemic control can reduce the risk of serious micro- and
macrovascular complications in type 2 diabetes. However, many patients fail to
reach glycemic targets due partly to low efficacy and adverse effects of treatment
(such as hypoglycemia or weight gain). The aim of this analysis was to evaluate the
short-term cost-effectiveness of liraglutide versus sitagliptin, in terms of cost per
patient reaching a glycated hemoglobin (HbA1c) target with no hypoglycemia and
noweight gain after 52-weeks, based on a recently published trial.METHODS:Data
were taken froma randomized, controlled trial (NCT00700817) inwhich adultswith
type 2 diabetes (mean age 55 years, HbA1c 8.4%, BMI 33kg/m2) failing metformin
monotherapy were randomly allocated to receive either 1.2mg liraglutide, 1.8mg
liraglutide or 100mg sitagliptin daily in addition to metformin. For the cost-effec-
tiveness analysis, the proportion of patients achieving a clinically relevant com-
posite endpoint, defined as HbA1c7.0%, with no reported hypoglycemia and no
gain in bodyweight, were estimated using logistic regression. Costs of antidiabetes
medications were accounted based on published wholesale acquisition costs in
2011USdollars ($).RESULTS:Trial data showed that 38.9% of patients on liraglutide
1.2mg and 49.9% on liraglutide 1.8mg achieved the composite endpoint, compared
with 18.6% on sitagliptin. Overall pharmacy costs (needle costs included) were
higher on liraglutide than sitagliptin.When expressed as themean cost per patient
reaching target HbA1c with no hypoglycemia or weight gain (cost of control), costs
were notably lower on liraglutide than on sitagliptin. Annual mean costs of control
were $9,632 on liraglutide 1.2mg and $10,933 on liraglutide 1.8mg, versus $14,711 on
sitagliptin.CONCLUSIONS:Themean cost per patient achieving control, defined as
reaching HbA1c target with no hypoglycemia or weight gain, was lower with lira-
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